✦ LIBER ✦

The argument for using high purity Factor VIII and IX concentrates in haemophilia

✍ Scribed by C.A. LEE

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An open clinical study assessing the eff

✍ T. LISSITCHKOV; M. MATYSIAK; K. ZAWILSKA; L. GERCHEVA; A. ANTONOV; M. MONTAÑES; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

No Detectable Alterations in Immunogenic

✍ I. R. MacGregor; L. E. McLaughlin; M. C. MacGregor; C. V. Prowse; D. S. Pepper 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 811 KB

Pharmacokinetics of Optivate®, a high-pu

✍ A. DMOSZYNSKA; A. HELLMANN; T. BAGLIN; D. O’SHAUGNESSY; J. TRELINSKI; K. KULICZK 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB

Inhibitor development in haemophilia A:

✍ J. GOUDEMAND 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB

Clinical assessment of Optivate®, a high

✍ A. DMOSZYNSKA; K. KULICZKOWSKI; A. HELLMANN; J. TRELINSKI; J. KLOCZKO; T. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB

Pharmacokinetic study of a high-purity f

✍ J. A. AZNAR; N. CABRERA; M. MATYSIAK; K. ZAWILSKA; L. GERCHEVA; A. ANTONOV; M. M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB